• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FLUOXETINE Drug Record

  • Summary
  • Interactions
  • Claims
  • FLUOXETINE chembl:CHEMBL41 Approved

    Alternate Names:

    NSC-283480
    FLUOXETINE
    SYMBYAX
    SARAFEM
    PROZAC
    PROZAC®
    chemidplus:54910-89-3
    rxcui:4493
    chembl:CHEMBL41
    pubchem.compound:3386
    drugbank:00472

    Drug Info:

    Year of Approval 1987
    Drug Class antidepressive agents, second-generation
    Drug Indications antidepressant,for treatment of bipolar disorder
    Drug Indications for treatment of autism
    FDA Approval approved
    Drug Class Small molecule
    Drug Indications antidepressant
    FDA Approval not approved
    Drug Class Small Molecule
    Drug Indications for treatment of sleep apnea
    (4 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
    Gobbi et al., 1997, Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats., Naunyn Schmiedebergs Arch. Pharmacol.
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Gören et al., 2007, Fluoxetine partly exerts its actions through GABA: a neurochemical evidence., Neurochem. Res.
    Sanders et al., 2007, Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward., Neuropsychopharmacology
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Mirza et al., 2007, Serotonin transporter density and anxiolytic-like effects of antidepressants in mice., Prog. Neuropsychopharmacol. Biol. Psychiatry
    Richman et al., 2007, Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation., Epilepsy Res.
    Iceta et al., 2007, Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells., Life Sci.
    Ranganathan et al., 2001, Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine., J. Neurosci.
    Gassó P et al., 2017, Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine., Prog Neuropsychopharmacol Biol Psychiatry
    Thomas D et al., 2002, The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels., J Pharmacol Exp Ther
    Rajamani S et al., 2006, Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine., Br J Pharmacol
    Chiu et al., 2004, Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels., J. Pharmacol. Sci.
    Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
    Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics
    Ha et al., 2006, Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells., Neurosci. Lett.
    Tsai SJ et al., 2008, Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder., Pharmacogenomics J
    Liu Z et al., 2007, Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders., Neurosci Lett
    Bahramali E et al., 2016, Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial., Eur J Clin Pharmacol
    Uz et al., 2005, Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum., Neuroscience
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
    Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
    Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
    Gassó P et al., 2014, Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients., Pharmacogenomics J
    Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
    Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
    Di Benedetto et al., 2007, Alterations of CREB and DARPP-32 phosphorylation following cocaine and monoaminergic uptake inhibitors., Brain Res.
    Lauterio et al., 1993, Fluoxetine induced insulin-like growth factor II (IGF-II) changes in hypothalami of normal, exercised and food restricted rats., Regul. Pept.
    Hong CJ et al., 2006, Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder., Pharmacogenomics J
  • FLUOXETINE   PPP1R1B

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17125745


    Sources:
    NCI

  • FLUOXETINE   AANAT

    Interaction Score: 1.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15994025


    Sources:
    NCI

  • FLUOXETINE   REEP5

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • FLUOXETINE   SRP19

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • FLUOXETINE   TPH1

    Interaction Score: 1.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 23221997 19590397


    Sources:
    PharmGKB

  • FLUOXETINE   FKBP5

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20709156 15565110


    Sources:
    PharmGKB

  • FLUOXETINE   CRHR1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17258395


    Sources:
    PharmGKB

  • FLUOXETINE   SLC6A4

    Interaction Score: 0.48

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)
    Trial Name NPL-2008, Fluoxetine
    Trial Name fluoxetine HCl,Prozac

    PMIDs:
    17486443 17356573 9537821 11752352 17335951 17215106 17289086 11487610


    Sources:
    TdgClinicalTrial NCI TEND

  • FLUOXETINE   IGF2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8265809


    Sources:
    NCI

  • FLUOXETINE   SERPINE1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18794724


    Sources:
    PharmGKB

  • FLUOXETINE   NOS2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16413968


    Sources:
    NCI

  • FLUOXETINE   HTR4

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9228186


    Sources:
    NCI

  • FLUOXETINE   HTR1B

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28025020


    Sources:
    PharmGKB

  • FLUOXETINE   HTR1A

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19590397 16302021


    Sources:
    PharmGKB

  • FLUOXETINE   GSK3B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18195729


    Sources:
    PharmGKB

  • FLUOXETINE   ACE

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27262302


    Sources:
    PharmGKB

  • FLUOXETINE   BDNF

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20016225


    Sources:
    PharmGKB

  • FLUOXETINE   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • FLUOXETINE   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24663076 24192121 18215618


    Sources:
    PharmGKB

  • FLUOXETINE   KCNH2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    11805215 16967046 15272206


    Sources:
    PharmGKB

  • FLUOXETINE   HTR2A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name NPL-2008, Fluoxetine
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • FLUOXETINE   DRD1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLUOXETINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC FDA

  • FLUOXETINE   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLUOXETINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FLUOXETINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21393461


    Sources:
    DTC PharmGKB

  • FLUOXETINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TdgClinicalTrial: FLUOXETINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of sleep apnea
    Drug Class Small Molecule
    FDA Approval not approved

    Publications:

  • TEND: FLUOXETINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class antidepressive agents, second-generation
    Year of Approval 1987

    Publications:

  • NCI: FLUOXETINE

    • Version: 14-September-2017

    Alternate Names:
    C506 NCI drug code

    Drug Info:

    Publications:
    Gobbi et al., 1997, Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats., Naunyn Schmiedebergs Arch. Pharmacol.
    Uz et al., 2005, Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum., Neuroscience
    Lauterio et al., 1993, Fluoxetine induced insulin-like growth factor II (IGF-II) changes in hypothalami of normal, exercised and food restricted rats., Regul. Pept.

  • DTC: FLUOXETINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL41 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos

  • PharmGKB: fluoxetine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry

  • TTD: Fluoxetine

    • Version: 2020.06.01

    Alternate Names:
    D0TR5X TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL41

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Fluoxetine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21